MethylGene PIPE sets market alight
This article was originally published in Scrip
Executive Summary
Investors were clearly impressed with the news that MethylGene, the Canadian biopharmaceutical company, was able to raise Can$33.7 million ($34.5 million) in a private placement to institutional investors (private investment in public equity or PIPE), when it only had a market cap of $5.1 million and was effectively running on fumes. "There was clearly a disconnect between the value of our technology and where the stock was trading. We had Can$ 10 million in cash on 30 September last year and we told the market that we had cash resources to take us to the end of the first quarter," president and ceo Charles Grubsztajn told Scrip.
You may also be interested in...
AI Firm Healx Raises $56M To Develop Affordable Rare Disease Treatments
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Abalos Raises €12M Series A To Develop Arenavirus-Based Cancer Therapies
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Despite BMS Bid, Celgene Pays $75m Upfront For Immatics Assets Options
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.